Anastasios Stathis

Any wrong or incomplete data? Any missing, misplaced, unlicensed picture? Please report any abuse, inaccuracy or lack of information to info@ticinoscienza.ch

1) IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma

Haematologica, 22 febbraio 2024

2) Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma

Human Vaccines & Immunotherapeutics, 31 dicembre 2023

3) The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib

British Journal of Haematology, 27 novembre 2023

4) PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine

bioRxiv, 16 novembre 2023

5) The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type

Exploration of Targeted Anti-tumor Therapy, 2021

6) ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms

bioRxiv, 2 gennaio 2023

7) In vitro anti-lymphoma activity of the first-in-class pan-NOTCH transcription inhibitor CB-103

British Journal of Haematology, 9 dicembre 2022

8) Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis

Haematologica, 1 novembre 2022

9) A systematic review of contemporary phase I trials in patients with lymphoma

Critical Reviews in Oncology / Hematology, 17 ottobre 2022

10) Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma

eJHaem, 27 luglio 2022

11) SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma

Blood Advances, 12 luglio 2022

12) Report of the First International Symposium on NUT Carcinoma

Clinical Cancer Research, 13 giugno 2022

13) Genetic and phenotypic attributes of splenic marginal zone lymphoma

Blood, 3 febbraio 2022

14) A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström’s macroglobulinemia

Leukemia & Lymphoma, 19 gennaio 2022

15) A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas

Leukemia & Lymphoma, 19 agosto 2021

19) Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors

Blood Advances, 25 maggio 2021

20) Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

The Lancet Oncology, 11 maggio 2021

21) Adverse Event Reporting with Immune Checkpoint Inhibitors in Older Patients: Age Subgroup Disproportionality Analysis in VigiBase

Cancers, 6 marzo 2021

22) Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models

Haematologica, 1 novembre 2020

23) A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B-cell lymphomas

Hematological Oncology, 26 ottobre 2020

24) Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734

Blood Advances, https://ashpublications.org/bloodadvances/article/4/17/4124/463605/Antitumor-activity-of-the-dual-BET-and-CBP-EP300

25) Targeting BET bromodomain proteins in cancer: The example of lymphomas

Pharmacology & Therapeutics, https://www.sciencedirect.com/science/article/abs/pii/S0163725820301613?via%3Dihub

26) An overview on anti-tubulin agents for the treatment of lymphoma patients.

Pharmacology and Therapeutics, https://www.sciencedirect.com/science/article/abs/pii/S0163725820300802?via%3Dihub

27) Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models.

American Society of Hematology, https://ashpublications.org/bloodadvances/article/4/5/819/452604/Copanlisib-synergizes-with-conventional-and

28) Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?

International Journal of Molecular Sciences, 5 febbraio 2020

Anastasios Stathis
is currently collaborating with
Istituto Oncologico Svizzera Italiana (IOSI) (Rif. IOSI)
Via Gallino 12 (ex Via Ospedale)
6500 Bellinzona

Anastasios Stathis
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently participating in the Research Group
Unità sviluppo nuovi farmaci
as Group Leader [Rif. 55110]